

CURRICULUM VITAE

Kenneth P. Klinker

Florida Licensure: PS 0031674

Work Address:

University of Florida, College of Pharmacy
1225 Center Drive
Gainesville, FL
(352)-294-5157
e-mail: klinkkp@cop.ufl.edu

Home Address:

4085 SE 39th Circle
Ocala, FL 34480
(352)-226-7670

EMPLOYMENT EXPERIENCE

Clinical Associate Professor
University of Florida College of Pharmacy
Clinical Specialist, Infectious Diseases
UF Health Shands Hospital

November 2009 - present

Responsibilities include development and enhancement of the Antimicrobial Management Program, and contribute to the training of Infectious Diseases Fellows, Pharmacy Residents, and Doctor of Pharmacy Students.

Co-Director of Antimicrobial Pharmacokinetics Service
UF Health Shands Hospital

November 2009 – present

Responsibilities include evaluating and monitoring patients receiving aminoglycoside and/or vancomycin therapy, train physicians and pharmacists on pharmacokinetics of aminoglycoside/vancomycin, education pharmacists and Pharmacy residents on implementing and maintaining a Pharmacokinetics service.

Residency Program Director – Infectious Diseases
UF Health Shands Hospital

July 2010 – present

Serve as the program director for an ASHP accredited residency program. Responsibilities include the development of programmatic goals, policies, and training modules for pharmacists interested in post-graduate training in Infectious Diseases.

Scientific Affairs Liaison – Ortho-McNeil

October 2007 – October 2009

Responsibilities include the provision of objective scientific information and education to internal and external partners; build relationships with key opinion leaders; identify research opportunities; deliver scientific voice of customer.

Clinical Specialist, Infectious Diseases

January 2003 – October 2007

UF Health Shands Hospital

Clinical Assistant Professor

University of Florida College of Pharmacy

Responsibilities included participation in Infectious Diseases Consult Service, Secretary of Anti-Infective Subcommittee, implementation of Anti-infective Stewardship Program, patient education, contributing to the training of Infectious Diseases Fellows, Pharmacy Residents, and Doctor of Pharmacy Students.

Clinical Specialist, Critical Care

October 1998 – January 2003

Clinical Assistant Professor

University of Florida College of Pharmacy

Responsibilities included active participation in patient care; developing and implementing cost-effective pharmacotherapy regimens; disseminating drug information; contributing to the training of medical staff, pharmacy residents, and Doctor of Pharmacy students through didactic and experiential instruction.

United States Navy

November 1987 – November 1989

EDUCATION/TRAINING

Adult Internal Medicine Residency

July 1997 – June 1998

UF Health Shands Hospital

Pharmacy Practice Residency

July 1996 - June 1997

UF Health Shands Hospital

Doctor of Pharmacy

May 1996

University of Maryland at Baltimore, School of Pharmacy

PUBLICATIONS

Shah KJ, Cherabuddi K, Shultz J, Borgert S, Ramphal R, **Klinker KP**. (in press). Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin resistant *enterococcus spp* (VRE): a single-center university hospital experience. *Int J Antimicrob Agents*.

DOI: <http://dx.doi.org/10.1016/j.ijantimicag.2017.06.008>

Klinker KP, Venugopalan V. Antimicrobial stewardship begins at the door: Promoting prudent antimicrobial use in the emergency department. *The APUA Newsletter*. 2017;35(1):3-6.

Jeon Nakyung, Staley B, **Klinker KP**, Hincapie-Castillo J, Winterstein AG. Acute kidney injury risk associated with piperacillin-tazobactam compared with cefepime during vancomycin therapy in hospitalized patients: Cohort study stratified by baseline kidney function. *Int J Antimicrob Agents*. 2017;50:63-67.

Hamadeh I, **Klinker KP**, Borgert SJ, Richards AM, Li W, Mangal N, Hiemenz JW, Schmidt S, Langae TY, Peloquin CA, Johnson JA, Cavallari LH. (in press). Impact of the CYP2C19 Genotype on Voriconazole Exposure in Adults with Invasive Fungal Infections. *Pharmacogenet Genomics*. 2017;27:190-196.

Zasowski EJ, Trinh TD, Claeys KC, Casapao AM, Sabagha N, Lagnf AM, **Klinker KP**, Davis SL, and Rybak MJ. Multicenter observational study of ceftaroline fosamil for methicillin-resistant *Staphylococcus aureus* bloodstream infections. *Antimicrob Agents Chemother*. 2017;61: pii: e02015-16.

Bosso JA, Casapao AM, Edwards J, **Klinker KP**, et al. Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: A roundtable discussion. *Hosp Pract*. 2016; DOI: 10.1080/21548331.2016.1230466

Pardo J, **Klinker KP**, Swift B, Borgert SJ, et al. Moving closer to zero: Effect of "just in time" dosing of prophylactic antibiotics on surgical site infections. *Hosp Pharm* 2016;51:44-48.

- Klinker KP**, Borgert SJ. Beyond vancomycin: The tail of the lipoglycopeptides. *Clin Ther* 2015;37:2619-2636.
- Pardo J, **Klinker KP**, Borgert SJ, et al. Clinical and economic impact of antimicrobial stewardship interventions with the Filmarray blood culture identification panel. *Diagn Microb Infect Dis* 2016;84:159-64.
- Espinel-Ingroff A, Alvarez-Fernandez M, Canton E, Carver PL, Chen SC, Eschenauer G, Getsinger DL, Gonzalez GM, Govender NP, Hansen KE, Kidd SE, **Klinker K**, et al. Multicenter study of epidemiological cutoff values and detection of resistance in *candida* spp. to anidulafungin, caspofungin, and micafungin using the sensititre yeastone colorimetric method. *Antimicrob Agents Chemother* 2015;59:6725-32.
- Trinh T, **Klinker KP**. Antimicrobial stewardship in the emergency Department. *Infect Dis Ther.* 2015;4:S39-S50.
- Trinh T, **Klinker KP** (2015, Spring). Antimicrobial stewardship in the emergency department. MAD-ID Newsletter,5(1):5-16.
- Desear KE, Weitzel K, Borgert SJ, LeClaire AC, Hatton RC, **Klinker KP**. Evaluation of an interactive educational model to enhance antimicrobial stewardship at an academic medical center. *J Pharma Care Health Sys* 2015.S2:S2-001. doi:10.4172/jpchs.1000-S2-001
- Gravenstein N, Fish JT, **Klinker KP**, et al. Prophylactic antibiotic administration: Is it time to infuse our practices with new approaches. *Anesthesia & Analgesia* 2015;120:709-711.
- Pardo J, **Klinker KP**, Borgert SJ, et al. Detection of *Neisseria meningitidis* from negative blood cultures and cerebrospinal fluid with the FilmArray Blood Culture Identification Panel. *J Clin Micro* 2014;52(6):2262-2264.
- Casapao A, Davis S, Barr V, **Klinker K**, et al. A large multicenter evaluation of the effectiveness and safety of ceftaroline fosamil therapy for severe infections. *Antimicrob Agents Chemother.* 2014;58(5):2541-2546.
- Eschenauer G, Ngyuen MH, Shoham S, Vazquez J, Morris A, Psculle W, Kubin C, **Klinker K**, et al. Real-world experience with echinocandin MIC's against candida species: A multi-center study of hospitals that routinely perform susceptibility testing of bloodstream isolates. *Antimicrob Agents Chemother* 2014;58(4):1897-1906.
- Guervil D, **Klinker KP**, Borgert SJ, et al. Measuring quality metrics to identify and monitor antimicrobial stewardship program quality improvement efforts. *Infect Control Hosp Epidemiol* 2014;35(1):101-103.
- Pardo J, **Klinker KP**, Borgert SJ, et al. Time to positivity of blood culture supports antibiotic de-escalation at 48 hours. *Ann Pharmacother* 2014;48(1):33-40.
- McCullough B, Wiggins L, Richards A, **Klinker K**, et al. Aztreonam for febrile neutropenia in patients with beta-lactam allergy. *Trans Infect Dis* 2014;16(1):145-152.
- Eschenauer GA, Carvel PL, Lin SW, **Klinker KP**, et al. Fluconazole versus an echinocandin for *Candida glabrata* fungemia: a retrospective cohort study. *J Antimicrob Chemotherapy.* 2013;68(4):922-6.
- Snyder AM, **Klinker KP**, Orrick JJ, Janelle J, and Winterstein AG. An in-depth analysis of medication errors in hospitalized patient with HIV. *Ann Pharmacother* 2011;45:459-468.
- Klinker KP**, Harbilas JW, Johns TE. "Drug-Induced Hematologic Disorders". In *Pharmacotherapy: A pathophysiologic approach*. Ed JT Dipiro, et al, New York, New York:McGraw-Hill, 2002. 1783-96.
- Klinker KP**, Johns TE. Antihypertensive therapy made easier. *Patient Care* 1999; 32(11): 109-10,13-14,16,21-22,24.
- Klinker KP**, Johns TE. Fixed-dose antihypertensives: What you need to know. *IM Int Med* 1998; 19(10): 15-20,25-6.
- Klinker KP**. What are common drug interactions associated with HIV pharmacotherapy? *Fla J Hlth-Syst Pharm* 1997;15(9):22-3.

Submitted for review

In Preparation

McKamey, **Klinker KP**, Borgert SJ, Iovine NM, Cherabuddi K. Cefepime for the Treatment of Bacteremia Caused by AmpC producing *Enterobacteriaceae*.

Worrall S, **Klinker KP**, Voelkner A, Lagasse C, Borgert S, Derendorf H. Assessment of beta-lactam induced nephrotoxicity.

Venuogopalan V, Klinker KP, Borgert SJ, Cherabuddi K. Stability of continuous infusion meropenem.

Journal article peer reviewer

Clinical Therapeutics; Pharmacotherapy; Infectious Diseases and Therapy; International Journal of Infectious Disease, PLOS ONE

TEACHING EXPERIENCE

Course (year)	Lecture
PHA 5755 – Principles of Medical Microbiology, Virology, and Immunology	
2016 -	Diagnosing bacterial infections (1 hr) Rapid Diagnostic Tests (1 hr) Pleomorphic bacteria (0.5 hrs) Neisseria spp (0.25 hrs) Helicobacter pylori (0.25 hrs) Legionella/Mycoplasma (0.5 hrs) Chlamydia (0.25 hrs) Yersinia (0.5 hrs) Mycobacteria (0.5 hrs)
PHA 5782C – Patient Care 2 (Module 1 – Introduction to ID Coordinator)	
Pharmacology 2016 –	Penicillins (1 hr) Monobactams (0.25 hrs) Carbapenems (0.5 hrs) Aminoglycosides (0.5 hrs) Fluoroquinolones (0.75 hrs) Sulfonamides (0.5 hrs) Urinary agents (0.5 hrs) Polymixins (0.5 hrs)
Pharmacotherapy	Urinary tract infections: Acute cystitis (0.5 hrs) Antimicrobial Stewardship (0.5 hrs) Surgical Prophylaxis (0.5 hrs)
PHA 5783 – Pharmacotherapy III	
2016 2016 2013 – 2016 2015 – 2016	Bacterial meningitis (1 hr) Urinary tract infections (1 hr) Endocarditis (1 hr) Antimicrobial Stewardship (1 hr)
PHA 5784 – Pharmacotherapy IV	
2012 – 2016 2004 1997	Pharmacokinetics Main Case (4 hrs) Community acquired pneumonia Main Case (4 hrs) HIV Case Presentation (4 hrs)
PHA 5787 – Pharmacotherapy V	
2013 – 2015 2005	Pneumonia Main Case (4 hrs) Endocarditis Main Case (4 hrs)
PHA 5127 – Basic Principles of Dose Optimization I	
2002	Vancomycin pharmacokinetics (2002)
PHA 5782 – Pharmacotherapy II	
2000 1999	Electrolyte/Fluid Imbalance Acid Base Disorders
UF College of Medicine: Division of Infectious Diseases – ID Fellow Training	
2011 - 2015	Antimicrobial Stewardship; Introduction to Antibacterial Managing Fungal Infections; Managing <i>Staphylococcus aureus</i> ; Managing <i>Pseudomonas aeruginosa</i>

INDEPENDENT STUDIES/PROJECTS

Implementation of a Beta-Lactam Therapeutic Drug Monitoring Program (2017)
UF Health Shands Hospital, Gainesville, FL

Impact of an Extended Infusion Beta-lactam Strategy on Outcomes in Critically Ill Patients with Pseudomonas Infections (2017)
UF Health Shands Hospital, Gainesville, FL

Evaluating clinical outcomes in patients receiving cefepime for the management of bacteremia secondary to AmpC producing organisms (2016)
UF Health Shands Hospital, Gainesville, FL

Development of an electronic antimicrobial stewardship scoring tool to identify patients for pharmacist intervention (2016)
UF Health Shands Hospital, Gainesville, FL

Early Experience with Ceftaroline Therapy at an Academic Hospital System (2016)
UF Health Shands Hospital, Gainesville, FL

Rates of breakthrough fungal infections in high-risk hematologic malignancy and hematopoietic stem cell transplant recipients on voriconazole versus fluconazole prophylaxis (2015)
UF Health Shands Hospital, Gainesville, FL

Investigating the Impact of *CYP2C19*17* on Voriconazole Exposure in Patients with Invasive Fungal Infections (2015)
UF Health Shands Hospital, Gainesville, FL

Impact of rapid organism detection using FilmArray® improve patient outcomes (2014)
UF Health Shands Hospital, Gainesville, FL

Acute kidney injury associated with beta-lactam antimicrobials (2014)
UF Health Shands Hospital, Gainesville, FL

Sharing stewardship: Utilizing an enhanced interactive educational model to empower front-line pharmacists to take part in antimicrobial stewardship
UF Health Shands Hospital, Gainesville, FL

Evaluation of Patient Readmission after Outpatient Antimicrobial Therapy (OPAT)
UF Health Shands Hospital, Gainesville, FL

Retrospective analysis on the effectiveness of timing and redosing of antimicrobial prophylaxis on surgical site infections in class 1 and colorectal surgical procedures.
UF Health Shands Hospital, Gainesville, FL

Echinocandin minimum inhibitory concentrations: A multicenter descriptive analysis
UF Health Shands Hospital, Gainesville, FL

Multicenter Experience of the Effectiveness and Safety with Ceftaroline fosamil (CPT) Therapy
UF Health Shands Hospital, Gainesville, FL

Analysis of the time-to-positivity of blood cultures supports antibiotic de-escalation at 48 hours
Shands at the University of Florida, Gainesville, FL

Evaluation of microorganisms isolated from cancer patients with fever and chemotherapy-induced neutropenia presenting to the Emergency Department at the University of Florida
Shands at the University of Florida, Gainesville, Florida

Clinical response to vancomycin in patients with Methicillin-resistant *Staphylococcus aureus* bacteremia based on minimum inhibitory concentration.
Shands at the University of Florida, Gainesville, Florida

Cefepime for the treatment of bacteremia by extended-spectrum β -Lactamase (ESBL)-Producing Organisms
Shands at the University of Florida, Gainesville, Florida

Fluconazole for *Candida glabrata* fungemia: outcomes and comparison to echinocandin therapy
Shands at the University of Florida, Gainesville, Florida

Treatment of vancomycin resistant enterococcal urinary tract infections with ampicillin.
Shands at the University of Florida, Gainesville, Florida

Aztreonam for Febrile Neutropenia in Patients with Beta-Lactam Allergy
Shands at the University of Florida, Gainesville, Florida

Analysis of antimicrobial therapy in an intensive care unit in the absence of an antimicrobial stewardship program
Shands at the University of Florida, Gainesville, Florida

Evaluation of adverse drug events in patients with HIV admitted to a tertiary care institution
Shands at the University of Florida, Gainesville, Florida

Evaluation of fenoldopam in the prevention of renal dysfunction in patients undergoing thoracoabdominal aneurysm repair
Shands at the University of Florida, Gainesville, Florida

Assessment of patient outcomes after the implementation of a daily interruption sedation algorithm in a medical intensive care unit
Shands at the University of Florida, Gainesville, Florida

Comparison of 0.5mg versus 1.0 mg of TPA in clearing peripherally inserted central catheters.
Shands at the University of Florida, Gainesville, Florida

Conversion of Urokinase to TPA for the management of catheter associated occlusions.
Shands at the University of Florida, Gainesville, Florida

Development of a weight-based heparin nomogram for the management of DVT/PE.
Shands at the University of Florida, Gainesville, Florida

Pharmacoeconomic analysis of ibutilide for the management of atrial fibrillation.
Shands at the University of Florida, Gainesville, Florida

Cost effectiveness of IV nicardipine versus sodium nitroprusside in the management of postoperative hypertension.
Shands at the University of Florida, Gainesville, Florida

Physician attitudes toward pharmacist-managed anticoagulation clinics.
Shands at the University of Florida, Gainesville, Florida

PRESENTATIONS (Invited Lectures)

Antimicrobial Stewardship: Back to the Basics
Intravenous and Parenteral Nutrition and Antimicrobial Stewardship, Abu Dhabi, UAE, November 2016

Antimicrobial Stewardship: Clinical Scenario's
Intravenous and Parenteral Nutrition and Antimicrobial Stewardship, Abu Dhabi, UAE, November 2016

Daily Priority Planning for the ASP Practitioner
Making a Difference – Infectious Diseases, Orlando, Florida, May 2016

Beta-lactam therapeutic drug monitoring
Critical Care Grand Rounds, UF College of Medicine, March 2016

Quantifying ASP results for the C-suite: an ASP score card
Antibiotic Crossroads, Nashville, Tennessee, November 2015

Quantifying ASP results for the C-suite: an ASP score card

Making a Difference – Infectious Diseases, Orlando, Florida, May 2015

Healthcare associated pneumonia

Critical Care Grand Rounds, UF College of Medicine, January 2014

Re-implementing an Antimicrobial Stewardship Program: Shifting our Focus

University of Florida, College of Pharmacy, Gainesville, FL September 2012

Cost of managing methicillin resistant *Staphylococcus aureus* (MRSA).

NEFSHP Fall Meeting, Jacksonville, Florida, October 2006.

Management of Healthcare Associated Pneumonia: Role of the Pharmacist

GSHP Annual Meeting, Amelia Island, Florida, June 2006

Antimicrobial Stewardship Initiatives: Optimizing Antimicrobial Prescribing

FSHP Annual Meeting, Orlando, Florida August 2005

Impact of formulary decisions on bacterial resistance

From Pathology to Policy Conference, Atlanta, Georgia, November 2004

Managing serious infections in hospitalized patients

From Pathology to Policy Conference, Atlanta, Georgia, November 2004

Impact of resistant pathogens on the management of Nosocomial Pneumonia

Multidisciplinary Trauma Conference, Shands at UF, Gainesville, Florida, September 2004

Resistant gram-positive pathogens: What are our treatment options?

GSHP Spring Clinical Meeting, Atlanta, Georgia, April 2004

Review the management of extended spectrum beta lactamase producing organisms

Shands at Lake City, Lake City, Florida, July 2003

Acute decompensated heart failure case presentation

EFSHS Continuing Education Meeting, Daytona, Florida, April 2002

Sepsis case presentation

GSHP Continuing Education Meeting, Valdosta, Georgia, April 2002

Antibiotic therapy in the management of nosocomial pneumonia

SWGSHS Continuing Education Meeting, Columbus, Georgia, March 2002

The role of natriuretic peptides in the management of congestive heart failure

VSHP Continuing Education Meeting, Virginia Beach, Virginia, February 2002

The sepsis paradigm: Incorporating coagulation abnormalities

AISHS Continuing Education Meeting, Birmingham, Alabama, January 2002

Management of sepsis with recombinant human activated protein C

EFSHS Continuing Education Meeting, Daytona Beach, Florida, January 2002

Recombinant human activated protein C: Does it have a role in septic shock

AISHS Continuing Education Meeting, Huntsville, Alabama, January 2002

Management of septic shock

MPA Continuing Education Meeting, Ocala, Florida, November 2001

Sepsis: A shift toward coagulation

CFSHS Continuing Education Meeting, Tallahassee, Florida, October 2001

Decompensated congestive heart failure: Time for change.

Nova Southeastern Educational Conference, Fort Lauderdale, Florida, May 2001

Management of nosocomial pneumonia.

NEFSHP Continuing Education Meeting, Jacksonville, Florida, February 2001

POSTER PRESENTATIONS

Klinker KP, Bowden J, Venugopalan V. *Poster*. Implementation of a Beta-Lactam Therapeutic Drug Monitoring Program. Making A Difference - Infectious Diseases. Orlando, FL. May 11, 2017 - May 11, 2017.

Klinker KP, Carnely A, Venugopalan V, Cherabuddi K. *Poster*. Impact of an Extended Infusion Beta-lactam Strategy on Outcomes in Critically Ill Patients with Pseudomonas Infections. Making A Difference - Infectious Diseases. Orlando, FL. May 11, 2017 - May 11, 2017.

Lascano J, Cope J, **Klinker KP**, Trillo CA. Therapeutic drug monitoring for beta-lactams in cystic fibrosis. ATS International Conference, May 2017, Washington DC

McKamey L, **Klinker KP**, Borgert SJ, Iovine NJ, Cherabuddi K. Clinical utility of cefepime for the management of bacteremia secondary to ampC producing organisms. IDWeek, October 26 – 30, 2016, New Orleans, LA

Cherabuddi K, **Klinker KP**. A decade of antimicrobial stewardship at the University of Florida – Challenges, strategies, and outcomes. 17th International Congress on Infectious Diseases, March 2 – 5, 2016, Hyderabad, India.

Zasowski EJ, Claeys KC, Casapae AM, Sabagha N, **Klinker KP**, et al. Ceftaroline fosamil for the treatment of methicillin-resistant staphylococcus aureus pneumonia. Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-21, 2015, San Diego, CA.

Zasowski EJ, Claeys KC, Casapae AM, Sabagha N, **Klinker KP**, et al. Ceftaroline fosamil for the treatment of methicillin-resistant *staphylococcus aureus* bloodstream infections. Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-21, 2015, San Diego, CA.

Hamadeh I, Mangal N, Schmidt S, Langaee T, Peloquin C, Hiemenz J, **Klinker KP**, et al. CYP2c19*17 variant and voriconazole exposure in patients with invasive fungal infections. American College of Clinical Pharmacy Annual Meeting, October 12-15, 2014. Austin, TX.

Worrall SD, **Klinker KP**, Voelkner A, et al. Acute kidney injury associated with beta-lactam antimicrobials. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, 2014. Washington, DC.

Voelkner A, McCullough BJ, **Klinker KP**, et al. Evaluation of clinical outcome and AUC/MIC in patients receiving vancomycin for MRSA bacteremia. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, 2014. Washington, DC.

Voelkner A, McCullough BJ, **Klinker KP**, et al. Assessment of vancomycin AUC/MIC and clinical outcome in MRSA patients. Presented at the Globalization of Pharmaceuticals Education Network (GPEN). August 27-30, 2014. Helsinki, Finland

Pardo J, **Klinker KP**, Borgert SJ, et al. Does rapid organism identification and resistance gene testing directly from blood cultures improve patient outcomes. Presented at the American Society of Microbiology General Meeting. Boston, MA

Casapao AM, Davis SL, Barr VO, **Klinker KP**, et al. The Effectiveness and Safety with Ceftaroline fosamil (CPT) Therapy for Lower Respiratory Tract Infections (LRTI) in a Multicentre Study in the United States. Presented at the European Congress of Clinical Microbiology and Infectious Diseases. May 10-13, 2014. Barcelona, Spain.

Casapao AM, Davis SL, Barr VO, **Klinker KP**, et al. Multicenter Experience of the Effectiveness and Safety with Ceftaroline fosamil (CPT) Therapy. Accepted for poster presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy, September 10-13, 2013. Denver, CO.

McCullough B, **Klinker KP**, Borgert S, Rand K. Clinical Response to Vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteremia based on minimum inhibitory concentration. Presented at Infectious Diseases Society of America Annual Meeting, October, 2012. San Diego, CA. Abstract 869.

Shultz J, **Klinker KP**, Borgert S, Ramphal R. An analysis of the use of ampicillin for urinary tract infections caused by vancomycin resistant enterococcus. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9 – 12, 2012. San Francisco, CA. Abstract K274.

Lourdes L, Gopalan P, DeGroat J, Falgiani M, **Klinker KP**, Hiemenz J. Evaluation of the microorganisms isolated from cancer patients with fever and chemotherapy-induced neutropenia presenting to the Emergency Department at the University of Florida. Accepted for poster presentation at Infectious Diseases Society of America Annual Meeting, October, 2012. San Diego, CA. Abstract 757.

Guervil DJ, **Klinker KP**, Alnuaimat H, Peterson NT, Ramphal R. Analysis of antimicrobial therapy in an intensive care unit in the absence of an antimicrobial stewardship program. Presented at the Infectious Diseases Society of America Annual Meeting, October 19 -23, 2011. Boston, MA. Abstract 225

Klinker KP, Borgert S, Guervil D, Ramphal R. Re-implementing an Antimicrobial Management Team: Impact on Antimicrobial Consumption beyond a Restricted Antimicrobial Policy. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17 – 20, 2011. Chicago, IL. Abstract K1878.

Guervil D, **Klinker K**, Johns T. Impact of a standardized order form on the accuracy of oseltamivir prescribing. University HealthSystem Consortium Annual Conference, December, 2010. Anaheim, CA.

B. Staley, D. Schain, **K. Klinker**, C. Hansen, R. Ramphal. Impact of an Antimicrobial Management Program on Antibiotic Consumption and the Associated Effect on Resistance and Drug Costs. ICAAC, September 17-20, 2007, Chicago, IL.

Snyder AM, **Klinker KP**, Orrick JJ, Janelle J, Winterstein AG. Is the medication system in hospitals failing patients on HAART?. American College of Clinical Pharmacy Annual Meeting, October 26-29, St. Louis, MO.

Beyhan BM, LeClaire AC, **Klinker KP**, Layon AJ. Evaluation of recombinant human activated protein C in patients with severe sepsis at a tertiary care institution. American College of Clinical Pharmacy Spring Practice and Research Forum, April 2006. Monterey, CA.

Rand, K, Gaskins D, Pugh L, **Klinker K**. Notification of Potentially Life-Threatening Treatment Failure for Patients with Resistant Gram Negative Rod (GNR) Bacteremia by the Microbiology Laboratory Presented at the ASM Annual Meeting, June 2005, Atlanta, GA.

Klinker KP, Gonzalez-Rothi R, Hatton R, et al. The role of fenoldopam in preventing renal dysfunction following thoracoabdominal aneurysm repair. Presented at the American Thoracic Society International Meeting, Atlanta, Georgia, May 2002.

Patel-PG; **Klinker-KP**; Leather-HL; Johns-TE; Zumberg-M. Efficacy of 0.5 mg versus 1 mg tissue plasminogen activator (tPA) in clearing peripherally inserted central catheters (PICC). ASHP-Midyear-Clinical-Meeting (ASHP-Midyear-Clinical-Meeting); 2002; 37(DEC); P-86E.

Totleben-ER; Johns-TE; Orrick-JJ; Kahler-DA; **Klinker-KP**; Kilroy-RA. Design and implementation of a pharmacist competency assessment program. ASHP-Midyear-Clinical-Meeting; 2000; 35(Dec); PCM-1.

Klinker KP, Johns TE, Lipowski E, Lopez LM. Physician attitudes toward pharmacist-managed anticoagulation clinics. Presented at the American College of Clinical Pharmacy Annual Meeting, Phoenix, Arizona, November 1997.

PROFESSIONAL MEMBERSHIPS

Society of Infectious Diseases Pharmacists
Florida Society of Health-System Pharmacists
American Society for Microbiology

ACTIVITIES/AWARDS

SIDP

Antimicrobial Stewardship Committee	2015 - 2016
Political Advocacy Committee	2016 -
UF College of Pharmacy Curriculum Committee	2016 -
Making a Difference – Infectious Diseases	2015 -
FSHP Board of Directors	2003 - 2005
Phi Lambda Sigma Leadership Fraternity	2002
Honorary Member of the University of Florida Chapter	
FSHP/Forerunner of the Year Award	2002
Board Certified Pharmacotherapy Specialist	2000 - 2007
North Central Florida Society of Health-System Pharmacists	
Program Director/President Elect	January 2000
President	January 2001
FSHP/Glaxo Pharmacoeconomics Research Award	August 1998